|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||96.60 - 96.60|
|52-week range||88.75 - 112.65|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||17.88|
|Forward dividend & yield||3.86 (4.00%)|
|Ex-dividend date||05 May 2021|
|1y target est||N/A|
Suzanne Judd, Ph.D., Epidemiologist at the University of Alabama at Birmingham School of Public Health, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
More COVID-19 vaccines could be on the way. While hundreds of millions of people around the world have received shots from the vaccines that are already approved or authorized, several other vaccine candidates are currently in late-stage testing. In this Motley Fool Live video, recorded on Sept. 8, Fool contributors Keith Speights and Brian Orelli discuss five stocks to watch that could be winners if those late-stage clinical trials are successful.
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.